Louis Ignarro Net Worth

The estimated Net Worth of Louis Ignarro is at least $78.5 mil dollars as of 7 August 2020. Louis Ignarro owns over 700,000 units of LadRx Corp stock worth over $78,518 and over the last 21 years he sold CYTR stock worth over $0. In addition, he makes $0 as Independent Director at LadRx Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Louis Ignarro CYTR stock SEC Form 4 insiders trading

Louis has made over 1 trades of the LadRx Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 700,000 units of CYTR stock worth $182,000 on 7 August 2020.

The largest trade he's ever made was exercising 700,000 units of LadRx Corp stock on 7 August 2020 worth over $182,000. On average, Louis trades about 35,000 units every 0 days since 2003. As of 7 August 2020 he still owns at least 872,427 units of LadRx Corp stock.

You can see the complete history of Louis Ignarro stock trades at the bottom of the page.

Louis Ignarro biography

Dr. Louis J. Ignarro Ph.D. is Independent Director of CytRx Corporation. He previously served as a director of Global Genomics since November 20, 2000. Dr. Ignarro serves as the Jerome J. Belzer, M.D. Distinguished Professor of Pharmacology in the Department of Molecular and Medical Pharmacology at the UCLA School of Medicine. Dr. Ignarro has been at the UCLA School of Medicine since 1985 as a professor, acting chairman and assistant dean. Dr. Ignarro received the Nobel Prize for Medicine in 1998. Dr. Ignarro received a B.S. in pharmacy from Columbia University and his Ph.D. in Pharmacology from the University of Minnesota.

How old is Louis Ignarro?

Louis Ignarro is 79, he's been the Independent Director of LadRx Corp since 2002. There are no older and 7 younger executives at LadRx Corp.

What's Louis Ignarro's mailing address?

Louis's mailing address filed with the SEC is 11726 SAN VICENTE BLVD., SUITE 650, , LOS ANGELES,, CA, 90049.

Insiders trading at LadRx Corp

Over the last 21 years, insiders at LadRx Corp have traded over $0 worth of LadRx Corp stock and bought 3,710,406 units worth $8,711,088 . The most active insiders traders include Steven A Kriegsman, Scott Bradford Patterson y Max Link. On average, LadRx Corp executives and independent directors trade stock every 177 days with the average trade being worth of $22,531. The most recent stock trade was executed by Earl W Brien on 14 August 2020, trading 150,000 units of CYTR stock currently worth $39,000.

What does LadRx Corp do?

Complete history of Louis Ignarro stock trades at LadRx Corp

LadRx Corp executives and stock owners

LadRx Corp executives and other stock owners filed with the SEC include:

• Steven Kriegsman,
  Chairman of the Board, Chief Executive Officer
• Steven A. Kriegsman,
  Chief Exec. Officer
• John Caloz,
  Chief Financial Officer, Chief Accounting Officer, IR Contact Officer
• John Y. Caloz,
  CFO, Treasurer & Sr. VP
• Louis Ignarro,
  Independent Director
• Joel Caldwell,
  Director
• Earl Brien,
  Director
• Dr. Felix Kratz Ph.D.,
  Sr. VP, Drug Devel.
• Cristina Newman,
  Corp. Sec.
• Terri Stevens,
  Chief Bus. Officer
• Molly Painter,
  Pres of USA and Head of Launch & Commercial Operations
• Molly Carey Poarch,
  Global & U.S. Head of Corp. Communications
• Jennifer K. Simpson,
  Director
• Anita J Chawla,
  Director
• Daniel J Levitt,
  Chief Medical Officer
• Joseph Rubinfeld,
  Director
• Olivia C Ware,
  Chief Commercial Officer
• Douglas Scott Wieland,
  Sr. VP - Drug Development
• Felix Kratz,
  Vice President Drug Discovery
• Herbert H Jr Mcdade,
  
• Alexander L Cappello,
  Director
• Raymond C Jr Carnahan,
  
• Ben Levin,
  Gen.Cnsl/VP Legal Affairs/Secy
• Eric Jay Selter,
  Director
• Cheryl Cohen,
  Director
• Scott Bradford Patterson,
  10% owner
• Marvin R Selter,
  Director
• Richard J Wennekamp,
  Director
• Max Link,
  Director
• David Scott Geyer,
  Sr. V.P. of Manufacturing
• Mitchell K Fogelman,
  Chief Financial Officer
• Jack R Barber,
  Sr VP - Drug Development
• Shi Chung Ng,
  Sr. VP Research & Development
• Matt Natalizio,
  Chief Financial Officer
• Mark Tepper,
  Vice President
• Stephen Snowdy,
  Chief Executive Officer